Clinical trial
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly…
NCT00363090 · Toronto Sunnybrook Regional Cancer Centre, Other · Unknown status
Key facts
| NCT number | NCT00363090 |
|---|---|
| Title | Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma |
| Official title | Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study |
| Lead sponsor | Toronto Sunnybrook Regional Cancer Centre, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Other |
| Interventions | alemtuzumab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, flow cytometry, pharmacological study |
| Enrollment | 84 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2010 |
| First posted | Aug 15, 2006 |
| Last update posted | Sep 20, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: